The 22% OID and nine-month maturity on the convertible note imply severe cash constraints — monitor for potential additional equity draws or covenant events. The registration rights agreement obligates the company to file a resale registration statement within 30 days and achieve effectiveness within 60-90 days, which could accelerate share overhang. Watch for liquidity pressure and further dilutive financing rounds given the $5M market cap relative to the $2M raise.
Price Chart
Executive Summary
Glucotrack raised $2,000,000 through a private placement of Units at $0.75 per Unit, each consisting of one share (or pre-funded warrant) and a 5-year warrant exercisable at $1.50/share, and concurrently issued a senior secured convertible promissory note with a 22% original-issue discount and 8% interest, maturing nine months from July 14, 2026. The $2M gross proceeds represent ~40% of the company's $5M market cap, and the punitive 22% OID on the note signals acute financial distress — together these create severe near-term dilution and cash-flow pressure on a micro-cap issuer.
Key Financial Metrics
Key Facts
- Total gross proceeds of $2,000,000 from the sale of Units at $0.75 per Unit
- Each Unit includes one share (or pre-funded warrant at $0.0001) and one 5-year common warrant exercisable at $1.50/share
- A senior secured convertible promissory note was issued with 22% original-issue discount and 8% interest (18% post-default)
- Convertible note matures nine months from the effective date of July 14, 2026
- Per-unit purchase price of $0.75 is deeply discounted relative to implied valuation at a $5M market cap
- Proceeds to be used for working capital, strategic investments, and acquisitions
- Registration rights granted for resale of shares and warrant shares
Financial Impact
$2,000,000 gross proceeds (40% of $5M market cap) with 22% OID on the convertible note, representing highly dilutive distressed financing
Risk Factors
- Massive dilution from the $2M unit offering relative to a $5M market cap
- Punitive 22% OID on the convertible note signals extreme financing distress
- Warrants exercisable at $1.50/share create additional overhang if the stock trades above that level
- Short nine-month note maturity creates refinancing risk if cash flows do not improve
- Registration rights could accelerate share resales, pressuring the stock further
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036218 |
| Exhibit: ex10-2.htm | 0001493152-26-036218 |
| Exhibit: ex4-2.htm | 0001493152-26-036218 |
| Exhibit: ex4-1.htm | 0001493152-26-036218 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.4032 | awaiting T+60 | — | $1.71 (−324.11%) |
Oct 19, 2026 8d ago | 8-K | $0.6511 | awaiting T+60 | — | $1.71 (+162.63%) |
Oct 13, 2026 14d ago | S-1/A | $0.8873 | awaiting T+60 | — | $1.71 (−92.72%) |
Oct 13, 2026 14d ago | 425 | $0.8873 | awaiting T+60 | — | $1.71 (+92.72%) |
Sep 28, 2026 29d ago | 8-K | $1.74 | awaiting T+60 | — | $1.71 (−1.72%) |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | $1.71 (+6.04%) |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | $1.71 (+6.04%) |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | $1.71 (−15.76%) |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | $1.71 (−15.76%) |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | $1.71 (−25.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers